Oncology & Cancer

Response to lenalidomide often suboptimal in MDS/MPN-RS-T

(HealthDay)—Lenalidomide produces hematologic responses in myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) with ring sideroblasts (RS) and thrombocytosis (MDS/MPN-RS-T), although these responses are often ...

Oncology & Cancer

New myeloma treatment options show promise

(HealthDay)—New multiple myeloma treatment options appear promising for patients aged 65 years and younger and for newly diagnosed patients who are ineligible for stem-cell transplantation, according to two studies published ...

Oncology & Cancer

Treatment beneficial in smoldering multiple myeloma

(HealthDay)—For patients with smoldering multiple myeloma, treatment with lenalidomide plus dexamethasone correlates with delayed progression and improved survival, according to a study published in the Aug. 1 issue of ...

Oncology & Cancer

New drug improves survival in multiple myeloma relapse

Researchers at Moffitt Cancer Center and colleagues have investigated the safety, efficacy and the maximum tolerated dose of pomalidomide for patients with multiple myeloma who have disease relapsed after treatments with ...

Oncology & Cancer

New drug shows promise for myeloma patients

(HealthDay) -- Three new studies confirm that the drug lenalidomide can significantly lengthen the time that people with multiple myeloma experience no worsening of their disease, either after having a stem cell transplant ...

Oncology & Cancer

Chemo combination promising for multiple myeloma

(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according ...

page 2 from 4